Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2406940 | Vaccine | 2008 | 6 Pages |
Abstract
Mucosal vaccine formulations based on purified recombinant C280 γ-Intimin and EspB (Escherichia coli secreted protein B) from enterohaemorragic E. coli co-administered with a pegylated derivative of the TLR2/6 agonist MALP-2 (macrophage-activating lipopeptide) as adjuvant were evaluated in BALB/c mice. After intranasal vaccination, strong humoral and cellular immune responses were observed against C280 γ-Intimin and EspB. Sera of immunized mice inhibit bacterial haemolytic activity in vitro. Antigen-specific T-cell proliferation, IL-4, IL-2 and IFN-γ producing cells, and secretory IgA were mostly detected in animals receiving MALP-2 as adjuvant. These results suggest that C280 γ-Intimin and EspB are good candidate antigens to be incorporated into mucosal vaccines against this important pathogen.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Angel Cataldi, Tetyana Yevsa, Daniel A. Vilte, Kai Schulze, Mauricio Castro-Parodi, Mariano Larzábal, Cristina Ibarra, Elsa C. Mercado, Carlos A. Guzmán,